Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of parsaclisib in autoimmune hemolytic anemia

Ulrich Jäger • 10 Jun 2022
EHA 2022
Anemias Cold Agglutinin Disease Non-Malignant Parsaclisib

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the results of a study evaluating the safety and efficacy of parsaclisib for the treatment of warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Ulrich Jäger

2:33
The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
Ulrich Jäger • 16 Feb 2024
1:20
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
Ulrich Jäger • 16 Feb 2024
3:31
The role of lymphodepletion in CAR T-cell therapy: current knowledge & the need for personalization
Ulrich Jäger • 16 Feb 2024
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals